Prediction of Long-term Arm Morbidity Following Breast Cancer Surgeries and Treatments

November 14, 2025 updated by: Ifat Klein

Development of a Screening Tool for Prediction of Long-term Arm Morbidity Following Breast Cancer Surgeries and Treatments

Background: Breast cancer (BC) treatments usually include a combination of surgery, chemotherapy and radiation. These life-saving treatments cause high percentages of arm morbidity, which often lasts for months, or develops months after surgery. Arm and shoulder morbidity includes prolonged pain, restriction of movement, limitation of function and lymphedema (chronic progressive edema). All of these morbidities affect the quality of life (QOL) of the recovering patients and require lengthy care. Early detection of patients at risk and provision of proactive treatment can improve the recovery process from surgery and oncology treatments.

Aim: To develop a screening tool for the early identification of women at high risk for prolonged arm morbidity following BC treatments (persistent pain, lymphedema, function deficits and decreased range of motion), validate the tool, and examine the efficiency of intervention based on the the use of the tool.

Study Overview

Status

Completed

Conditions

Detailed Description

The development and the assessment of the screening tool will conduct in three stages:

  1. Systematic review and meta-analysis to identify from the literature risk factors for lymphedema, prolong pain, decreased range of motion (ROM), quality of life (QOL) and function after breast cancer (BC) treatments and surgery. Intended to understand which factor could be included in the screening tool.
  2. Development of the screening tool (study no. 1)- cross section study that will examine which of the risk factors found in the literature review/ meta-analysis will enter the tool. Women up to 3 years after BC surgery will be evaluated for arm morbidity (pain, lymphedema, limitation of movement and limitation of function), and their association to the risk factors, using an online questionnaire.
  3. A small cohort study (study no. 2)- Aimed to validate the screening tool. The study will be conducted at the hospital's oncology institute, and will recruit BC survivors who come for routine follow-up six months till three years after surgery. Patients will be asked to answer an online questionnaire, in addition, limb volume tests, strength and ROM will be performed at the clinic. A comparison will be made between the physical parameters that indicate the morbidity of the arm and the score found in the screening tool.
  4. A small prospective study (study no. 3)- The main goal of this study is to examine whether the use of the new questionnaire by the patients themselves will; A) affect the percentage of arrival to physical therapy (PT) treatments, B) will affect morbidity rates.

Study Type

Observational

Enrollment (Actual)

1602

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Israel
      • Tel Aviv, Israel, Israel, 6345415
        • Assuta Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Breast cancer patient six months till three years after surgery

Description

Inclusion Criteria:

  • Patients aged 18-75
  • Independent
  • Speaking Hebrew and Russian

Exclusion Criteria:

  • Patients who reported that from the time elapsed from the surgery they underwent additional surgery or an injury affecting the function/ pain of the arm.
  • Patients suffering from advanced metastatic disease, or background diseases that limit function.
  • Lymphedema prior to surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QuickDASH questionnaire
Time Frame: 18 months
a shortened version of the The Disabilities of the Arm, Shoulder and Hand (DASH), that contains 11 items measuring an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to her severity/function level. The the scores range from 0 (no disability) to 100 (most severe disability).
18 months
Numeric pain rating scale
Time Frame: 18 months
Pain scale reported by patients with rage of 0(no pain)-10(the worst possible pain imaginable).
18 months
The Godin-Shephard Leisure-Time Physical Activity
Time Frame: 18 months
divides the effort levels into light/ mild, moderate, strenuous and multiply by time per week.
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients diagnosed with lymphedema
Time Frame: 18 months
Diagnosis of lymphedema by a doctor / physical therapist
18 months
Shoulder range of motion
Time Frame: 18 months
Using DR Goniometer App evaluating ranges of motion in degrees between 0 (no range) to 180 (full range)
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Merav Ben- David, Professor, Assuta Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

May 1, 2025

Study Completion (Actual)

June 1, 2025

Study Registration Dates

First Submitted

March 19, 2023

First Submitted That Met QC Criteria

July 17, 2023

First Posted (Actual)

July 18, 2023

Study Record Updates

Last Update Posted (Actual)

November 17, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

July 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 0019-22ASMC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Subscribe